AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Assetmark Inc.

Assetmark Inc. reduced its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 95.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,406 shares of the medical device company’s stock after selling 27,910 shares during the quarter. Assetmark Inc.’s holdings in AtriCure were worth $39,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arcadia Investment Management Corp MI purchased a new stake in AtriCure in the 3rd quarter worth approximately $28,000. Comerica Bank grew its holdings in AtriCure by 70.5% during the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 1,043 shares in the last quarter. Quest Partners LLC lifted its stake in shares of AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after acquiring an additional 1,626 shares in the last quarter. nVerses Capital LLC raised its holdings in AtriCure by 733.3% in the third quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock valued at $140,000 after acquiring an additional 4,400 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC lifted its position in shares of AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock worth $222,000 after purchasing an additional 2,368 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Trading Down 0.9 %

AtriCure stock opened at $34.72 on Tuesday. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.00. The company’s fifty day moving average price is $30.08 and its two-hundred day moving average price is $25.43. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -41.83 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. The firm had revenue of $115.91 million for the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. During the same quarter last year, the firm posted ($0.20) EPS. The business’s quarterly revenue was up 17.9% on a year-over-year basis. On average, analysts forecast that AtriCure, Inc. will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATRC has been the topic of a number of research reports. Stifel Nicolaus dropped their price target on AtriCure from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. increased their price target on AtriCure from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Piper Sandler cut their price target on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Oppenheimer lifted their target price on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, UBS Group increased their target price on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.11.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.